Coagulation in Lymphatic System

Wendi Zhang1,2,3, Jiang Li4, Jiangjiu Liang1, Xiumei Qi5, Jinghui Tian6* and Ju Liu1,2*

1 Department of Gerontology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China, 2 Medical Research Center, Shandong Medicine and Health Key Laboratory of Microvascular Medicine, Institute of Microvascular Medicine, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China, 3 Graduate School, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, 4 Qeeloo Medical College, Shandong University, Jinan, China, 5 Department of Education, Shandong Provincial Qianfoshan Hospital, The First Hospital Affiliated With Shandong First Medical University, Jinan, China, 6 School of Public Health and Health Management, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China

The lymphatic system maintains homeostasis of the internal environment between the cells in tissues and the blood circulation. The coagulation state of lymph is determined by conditions of coagulation factors and lymphatic vessels. Internal obliteration, external compression or abnormally increased lymphatic pressure may predispose to localized lymphatic coagulation. In physiological conditions, an imbalance of antithrombin and thrombokinase reduces lymphatic thrombosis. However, the release of factor X by lymphatic endothelium injury may trigger coagulation cascade, causing blockage of lymphatic vessels and lymphedema. Heterogeneity of lymphatic vessels in various tissues may lead to distinct levels and patterns of coagulation in specific lymphatic vessels. The quantitative and qualitative measurement of clotting characteristic reveals longer time for clotting to occur in the lymph than in the blood. Cancer, infections, amyloidosis and lymph node dissection may trigger thrombosis in the lymphatic vessels. In contrast to venous or arterial thrombosis, lymphatic thrombosis has rarely been reported, and its actual prevalence is likely underestimated. In this review, we summarize the mechanisms of coagulation in lymphatic system, and discuss the lymphatic thrombosis-related diseases.

Keywords: coagulation, lymphatic endothelium, lymphatic thrombosis, lymph, lymphedema

INTRODUCTION

The mammalian lymphatic system is a one-way transport system of draining fluid and proteins from the interstitialspaces to the blood circulation. The lymphatic circulation is composed of lymphatic vessels, lymph nodes, lymphocytes, and associated lymphoid organs (1). This system is responsible for reabsorbing exudate tissue fluid from the vascular system through lymphatic capillaries. The fluid is then transported back to the bloodstream to replenish blood supply (2, 3). Although blood vessels and lymphatic vessels differ greatly in structure, they work together to maintain essential functions, including fluid and protein balance in tissues, cellular nutrition, and proper immune function (4). In blood vessels, the clotting mechanism is a protective mechanism for preventing excessive blood loss while maintaining blood flow (5). However, in the lymphatic vasculature, coagulation is a pathological phenomenon that is closely related to but quite different from blood clotting. In 1914, the presence of thrombin, fibrinogen, and other coagulation factors in the lymph was confirmed, indicating that lymph also has the ability to coagulate (6), while the mechanism of coagulation in the lymphatic system has not been thoroughly studied. In this review, we summarize the possible etiologies, processes, and associated diseases of lymphatic coagulation.
STRUCTURE AND FUNCTION OF THE LYMPHATIC SYSTEM

The lymphatic system is a unidirectional transit network consisting of a network of vessels and nodes. The lymphatic system is responsible for the reabsorption of plasma components leaking from capillaries and postcapillary venules into extracellular spaces (3). When the blood flows through the capillaries, the plasma proteins and part of the liquid are extruded from the vessels into the interstitial fluid because of hydrostatic pressure and osmotic pressure (7, 8). Most of the blood components are reabsorbed by the postcapillary venules, while a small portion is absorbed by the lymphatic capillaries to form the lymph (9).

The lymphatic capillaries are composed of monolayers of discontinuous endothelial cells, which having a relatively flat, “oak leaf” shape (10). The basal membrane is discontinuous and unclear, with no smooth muscle medium, thereby allowing greater permeability (11). The specialized discontinuous buttons junctions serve as anchoring sites at the sides of interdigitated flaps of adjacent oak leaf-shaped endothelial cells (12). The abluminal surface of lymphatic capillaries is notable directly connected to the extracellular matrix by anchoring filaments, which help maintain the shape of the lymphatic vessels and the flow of fluid as the pressure in the matrix changes (11, 13, 14). Pre-collecting lymphatic vessels, located in the deep dermis, drain fluid from the lymphatic capillaries (15). The pre-collecting lymphatics drain into the collecting lymphatic vessels, which are covered with a continuous basement membrane and lymphatic muscle cells. In contrast to capillaries, the collecting lymphatic vessels are lined with lymphatic endothelial cells interconnected by zipper-like junctions between the cell (1, 16, 17). The zipper-like junctions were composed of vascular endothelial cadherin and tight junction–associated proteins. These continuous zipper-like junctions with basement membrane and intraluminal valves prevent leakage or reflux of lymph during its transport (1, 18). The loosely apposed but overlapping borders of the lymphatic capillaries operate as primary valves that provide unidirectional fluid into lymphatics (19). The smooth muscle layer of collecting lymphatic vessels ensures that the phasic contractions propel lymph forward through the network (20). Action potentials in the lymphatic muscle cells elicit phasic contractions of the collecting lymphatic vessels (11). In addition, cyclical compression and expansion by the surrounding tissue significantly contributes to lymph propulsion, allowing lymph to through collecting pre-nodal lymphatic vessels, lymph nodes and collecting post-nodal lymphatic vessels, to replenish the blood cardiocirculatory system (1) (Figure 1A).

The primary function of the lymphatic system is to replenish the vascular system by regulating tissue fluid balance, facilitating interstitial protein transport, and providing essential immune function (21). To accomplish these functions, lymphatics move fluid and other contents from the interstitium to pass across the nodes and enter the great veins (20). Both extrinsic tissue compression and intrinsic contractions of the lymphatic muscle cells provide the lymphatic system with the energy necessary to overcome the opposing pressure gradients and propel lymph along the lymphatic network (22, 23). When lymphatic vessels are damaged or diseased, edema, fibrosis, immune disorders, nutritional failure, and other conditions may occur (3, 23).

BLOOD COAGULATION CASCADE

The normal blood coagulation process consists of three steps: vascular response, the initiation of platelet plugs, and the formation of fibrin clots (24). Platelet adhesion and aggregation at the site of vascular injury are necessary to stop bleeding (25). When blood vessels are injured, reactive vasoconstriction occurs first, reducing blood flow to the damaged area. Subcutaneous collagen components are also exposed, triggering platelet accumulation and activation (26). Exposure of blood vessel factor (TF) is the major physiological initiator of blood coagulation. It triggers the production of thrombin, which not only converts fibrinogen to fibrin but also activates platelets (27). Activated platelets secrete aggregatory mediators including thromboxane A2 and adenosine diphosphate. These mediators may provide ligands for platelet adhesion, diffusion, and activation when exposed to circulating blood (28, 29). Platelet adhesion and aggregation at the site of injury result in the formation of a primary “platelet embolism” and the binding of coagulation factors during the clotting cascade leads to the formation of a fibrin mesh. This mesh encapsulates and enhances the thrombus formation, prevents bleeding at the wound site, and promotes healing (30).

Coagulation includes both endogenous and exogenous pathways. Each pathway is initiated by different molecules, and both pathways converge into a common pathway that involves coagulation factors II, V, and X, leading to the formation of fibrin (31). Coagulation reactions start with exposure of TF-bearing cells to blood and continues mainly with activated platelets (32). After vascular endothelial injury, in the presence of calcium, factor IXa binds to factor VIIIa and activates factor X. Factor VIIa comes into contact with the exposed or expressed TF to form vitamin K-dependent enzyme complexes (28). The factor VIIa-TF complexes can also activate factor X directly or indirectly by activating factor IX, but its efficiency is much lower in the absence of factor VIIa. Activated factor X stimulates a small amount of prothrombin to form thrombin (30). At the initial stage of thrombin production, activation of platelets, factor V, and factor VIII trigger a very small amount of thrombin to cause a burst of thrombin production (32). Experiments have revealed that a large number of prothrombin-activated products were detected at a bleeding time of about 4 minutes (33).

Endothelial cells produce anticoagulants and procoagulant molecules to form structures that rapidly activate platelets and clot blood (34). Von Willebrand factor (vWF) is well-known for its crucial roles in hemostasis; it is synthesized in endothelial cells and stored in Weibel-Palade bodies (WPBs) (35, 36).

Abbreviations: CLEC-2, C-type lectin like receptor 2; GP Ib-IX, Glycoprotein Ib-IX; LYVE-1, Lymphatic vessel endothelial hyaluronan receptor 1; PAI, Plasminogen activator inhibitor; Prox1, Prospero homebox protein 1; RLD, The right lymphatic duct; TD, The thoracic duct; TF, Tissue factor; TFP, Tissue factor pathway inhibitor; TM, Thromboregulatory protein; u-PA, Urokinase-type plasminogen activator; VEGF, Vascular endothelial growth factor; VEGFR-3, Vascular endothelial growth factor receptor 3; vWF, Von willebrand factor; WPBs, Weibel-Palade bodies.
Platelet adhesion is mediated by vWF, which acts as a bridge between exposed subendothelial collagen and platelet receptors (32). The immobilized VWF attaches platelets to the injured area by binding to the glycoprotein Ib-IX complex on the platelet surface (37, 38). This process ultimately leads to a stable platelet adhesion through interaction with the platelet collagen receptors glycoprotein VI and glycoprotein la-IIa-integrin (39). Hemostasis is a balancing process of anticoagulant and procoagulant factors. On the one hand, quiescent endothelial cells express thromboregulatory protein (TM), tissue plasminogen activator (tPA), tissue factor pathway inhibitor (TFPI), and heparin sulfate. On the other hand, activated endothelial cells express TF, thrombin receptor, vWF, and plasminogen activator inhibitor-1 (PAI-1) to promote hemostasis (40, 41).

**FORMATION OF LYMPHATIC THROMBOSIS**

An imbalance consisting of an excessive concentration of antithrombin in the lymph and a low concentration of thrombokinase (activated coagulation factor X) greatly reduces the possibility of lymphatic thrombosis. The lack of anionic phospholipids on the cell surface and low concentrations of thrombinand TFPI also offset the production of fibrin in the lymph (42–44). Immunoelectron microscopy has illustrated that coagulation factor X is attached to the cell surfaces of lymphocytes under normal conditions (45, 46). Lymphatic thrombosis can be triggered by the lymphatic stream in contact with necrosis cells or by infection of the tissues in the neighborhood of the lymphatic vessels. Under these conditions accompanied by a low lymph flow or a hypercoagulable state, the release of coagulation factor X by the disintegration of the lymphatic endothelium significantly furnishes favorable conditions for thrombosis within the lymphatic vessels (42, 47). When necrotic cells in contact with the lymph stream, thromboplastin (i.e., tissue factor) is released and enters the lymph to activate factor VII (46, 48). When free factor VIIa binds to thromboplastin in the context of lymphatic endothelial cells membrane surface, its proteolytic activity is enhanced substantially (48). The factor VIIa-thromboplastin complexes activate factor X released by the injured lymphatic endothelium. Activated factor X stimulates to production of prothrombinand formations of thrombin, which facilitates the conversion of a large amount of fibrinogen into fibrin. Eventually, this process leads to the formation of a compact mass of fibrin containing lymphoid cells (43, 46, 49, 50) (Figure 1B). The formation of lymphatic thrombosis are supported by the release of thromboplastin substances from the injured lymphatic endothelium and the chronic obstruction of lymph flow in

![FIGURE 1 | Coagulation in lymphatic vessels. (A) Schematic diagram indicating the lymphatic capillaries with oak leaf-shaped endothelial cells and discontinuous button-like junctions. The collecting lymphatic vessels have continuous zipper-like junctions and lymphatic muscle cells coveragewhich contract and act as intrinsic lymphatic pump, hence facilitating lymph flow. (B) Thromboplastin (tissue factor) stimulates damaged lymphatic endothelial cells to release factor X and activates factor VII. Factor X is activated by factor VII-thromboplastin complexes and thromboplastin. Activated factor X helps to convert prothrombin to thrombin, which facilitates the conversion of fibrinogen into fibrin. Eventually, the fibrin mesh forms a dense fibrous protein mass that may cause a large number of embolisms of lymphoid cells.](image-url)
the presence of a hypercoagulable milieu, thus mirroring the
Virchow’s triad (hypercoagulability, stasis and endothelial injury)
(5, 51). Remarkably, there is an imbalance of low concentrations
of blood coagulation factors (e.g., factor V and VIII) and
high concentrations of anticoagulant molecules (e.g., TFPI,
antithrombin) in the lymph. The production and release of tissue
plasminogen activator tPA and PAI-1by lymphatic endothelial
cells exhibit high fibrinolytic activity. The fibrin generation is
largely counteracted by the unavailability of cell surface anionic
phospholipids such as those physiologically present on blood
platelets, combined with only low levels of coagulation factors,
and the strong inhibitory activity of heparin, antithrombin, and
tissue factor pathway inhibitor (46). The above mechanisms may
be the reasons why lymphatic coagulation is slower than blood
coaulation (52, 53).

Theoretically, any known cause of lymphatic vessel occlusion
due to internal obliteration, external compression, or increased
lymphatic pressure may predispose an individual to localized
lymphatic thrombosis (46). The venous pressure is higher than
the lymphatic pressure, and this may prevent further reflux of
blood into the lymph vessels to protect lymphatic function in
cases of lymphovenous valve dysfunction (54, 55). However,
lymphatic valves dysfunction may cause human lymphedema or
reflux of blood into the terminal parts of lymph ducts, followed by
coagulation. A recent experimental study revealed a new pathway
for platelet activation induced by the endothelial layer of the
lymph vessels. Platelet aggregation stabilizes thrombin to prevent
retrograde blood flow, resulting in thrombus formation at the
lymphovenous valve (56).

**Coagulation in Different Lymphatic Vessels**

Lymphatic vasculature displays remarkable heterogeneity
in structure and function. The primarily lymphaticcared right
lymphatic duct (RLD) and thoracic duct (TD). TD is the largest
lymphatic vessel that drains chylous and lymphatic fluid from
most of the human body including the limbs and abdomen (57).
The liver produces about 25–50% of the lymph flowing through
the TD (58). The liver is also the primary site of synthesis of all
clotting factors and their inhibitors, as well as several proteins
involved in fibrinolysis and anticoagulation (59, 60). This may
explain why the TD contains far more proteins and clotting
factors than the lymphatic ducts in the limbs, including the
axillary or inguinal lymphatics.

The analyses of lymphatic vessels in embryos, an dual origin
theory proposed that lymphatic endothelial cells originated from
two sources (61, 62). The study of mouse embryos and Xenopus
tadpoles also provide evidence that lymphatic endothelial cells
origin from both the veins and scattered mesodermal precursor
cell (63, 64). These studies demonstrate the existence of a separate
population of lymphatic endothelial cells with distinct molecular
and function identity that forms local lymphatic vessels (65).
Understanding the different lymphatic endothelial cells sources
is crucial, as distinct lymphatic endothelial cells will likely
contribute differentially to lymphatic thrombosis.

In contrast to blood, which is not in direct contact with
the cellular layers of parenchymal organs, the lymph is derived
directly from the organ interstitialfluid, whichbathes each organ’s
cellular layers (66, 67). That is, the lymph can actually provide
the different organ’s specific metabolic signature. The analysis
of the proteome, lipidome, and metabolome of lymph collection
from different parenchymal organs demonstrated differences in
the distribution of lymphatic fluid from different anatomical
areas (1). The composition of coagulation factors in lymph
also depends on the interstitial fluid in the surrounding tissues.
In addition, hemodynamic forces, pathological conditions, and
the extracellular environment may affect the lymphatic system,
leading to the adaptive changes (68). This may result in distinct
levels and patterns of coagulation of lymphatic vessels in
specific organs.

**Different Hemostatic Properties
For Lymphatic and Blood Coagulation**

**Platelets**

It is well-known that the platelets play an essential role
in the formation of white thrombus in circulating blood
(30). The lymph contains no platelets yet it is known that
thrombosis may occurwithin lympathics (42, 50, 51). Although
platelets are absent from the lymph, the human thoracic
duct lymph contains phospholipidcomponents similar to those
present at the plateletsurface. It is also suggested that the
lymphocytesresistent in the lymph were efficient surrogates of
bloodplatelets during lymphaticthrombosis (46, 69). However,
clearphysiological evidence for this theory is still lacking.

In the coagulation cascade of the blood, the embolus is
adherent to the vascular walls through platelet, leading to vessel
occlusion (39). The interaction between matrix-bound vWF and
its platelet receptor, adhesion glycoprotein Ib-IX (GPIb-IX),
is required for initial platelet adhesion (70). The lymph does
not contain platelets and its adhesionglycoproteinIb-IXcomplex,
therefore thrombus may stay in the lumen and not adhere to the
lymphatic wall. To date the location of the lymphatic thrombus
has not been thoroughly investigated. However, the lymphatic
thrombus is usually retained within the regional lymph nodes
(46). In contrast, dislodgement of the embolism from the blood
vessel may lead to distant vessel occlusive diseases (71).

**Von Willebrand Factor**

According to the existing literature, the ultrastructure of
lymphatic vessels in healthy humans does not contain WPBs.
Von Willebrand antigen was present in a very low concentration
in the rabbit limb lymph, primarily as low molecular weight
multimers (43). The presence of vWF in human dental pulp
lymph has been reported (72, 73), while other studies found
no lymphatic vessels in human dental pulp (74). The lymphatic
vascular hemophilia factor vWF is most likely to be produced
by lymphoendothelial cells at low concentrations, which may
also slow the formationof lymphatic thrombosis (37, 75–77). A
low concentration of vWF in lymphatic fluid may prevent the development of lymphoid thrombosis (52).

**Coagulation Factors**
As early as 1980, coagulation factors in thoracic-duct lymph of dogs were found to have significantly different coagulation activity from that typically measured in plasma (78). Both activity and concentration of most coagulation factors were confirmed to be dramatically reduced in lymph as compared with plasma (53). The percentages in lymph as compared with plasma were 5–20% activity and 20–40% antigen for factor V, factor VII, factor VIII, factor IX, factor X, fibrinogen and prothrombin (53, 79). The activity of factor VII in limb lymph was lower than the activity of factor X and of prothrombin despite the similar molecular weights and other properties of these three proteins (43). In animal experiments on lymph node transplantation in hemophilia dogs, data have revealed that lymph nodes have the ability to produce factor VIII and that lymphatic endothelial cells are the main source of factor VIII in extrahepatic tissue (80, 81). Especially, the lymph fibrinogen level of almost 30% of the mean plasma level (43). However, the fibrin generation is substantially inhibited by the unavailability of cell surface anionic phospholipids under physiological conditions in lymph, essentially making the lymph a hypocoagulable biological fluid. Moreover the low levels of factor VIII and factor V prevent the activation of factor X, thus preventing the generation of fibrin in lymph (43).

**D-Dimers**
The concentrations of coagulation factors and anticoagulation factors in the lymph were much lower than those in the plasma, but the concentration of d-dimer in the lymph was higher than that in the plasma, often more than fivefold (46, 53). Bach-Gansmo et al. have demonstrated that high d-dimer concentrations in the lymph occur during fibrinogen degradation mediated by human neutrophil elastase (82). This high level in lymph was not explored but may indicate proteolysis of fibrinogen and fibrin with release of D-like and D-dimer-like fragments in interstitial fluid (53).

**Antithrombins**
Lymphatic fluid is thought to have weaker clotting capability than blood because it contains little thrombokinase and high levels of antithrombin (42, 53). Although both plasma and lymph contained only very low concentrations of antithrombin-factor Xa complexes, their concentration in lymph exceeded their concentration in plasma. Moreover, anticoagulant-antithrombic glycosaminoglycans on lymph endothelium that could markedly potentiate antithrombin activity also may play an important role in preventing lymphatic thrombosis in vivo (43).

**TFPIs**
The lymph was found to contain two main anticoagulant protease inhibitors, antithrombin and TFPI. TFPI-Xa complex concentrations were higher in lymph than plasma, and mean lymph TFPI antigen in lymph was approximately twice the mean lymph TFPI activity. These results suggested factor X activation in interstitial fluid followed by its inactivation by TFPI. And TFPI-Xa complex inactivates the catalytic activity of VII-TF and prevents extravascular VIII-TF activating factor X from progressing to the generation of fibrin in the interstitial fluid and lymph of peripheral tissues (43, 53). It usually takes longer for clotting to occur in the lymph than in the blood (47) (Table 1).

**Lymphatic Endothelial Cell-Specific Molecules**
In recent studies, the lymphatic endothelial cell-specific membrane markers including lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), podoplanin, vascular endothelial growth factor receptor-3 (VEGFR-3) and specific intracellular factors such as Prox-1 have been found (83–85). The specific factors have been suggested as being able to permit the discrimination between blood and lymphatic microcapillaries in histological sections (86). However, whether these special molecules may be the inducement of lymphatic thrombosis remains to be clarified. Podoplanin is expressed in lymphatic endothelial cells and its expression is maintained by prosperhomeobox protein 1 (Prox1). Under inflammatory conditions, podoplanin expression is increased in lymphatic endothelial cells. In pathological status, the ectopic podoplanin expression is induced, whereas ectopic podoplanin-expressing cells migrate to the vicinity of vascular endothelial cells and interact with hyperpermeable vascular leaky platelets C-type lectin like receptor 2 (CLEC-2) facilitates thrombus formation (87). This pathologically expressed podoplanin may also participate in lymphatic thrombosis via interaction with leaky platelet CLEC-2, while it needs further investigation. Vascular endothelial growth factor (VEGF) was discovered by the use of a coagulation assay in 1990 as a factor that explains the localization of endothelium-dependent fibrin formation in tumors after TNF treatment (88). The urokinase-type plasminogen activator (u-PA) and PAI are active by VEGF (89) and tissue factor was demonstrated to control VEGF expression (90). A missense mutation in the tyrosine-kinase domain of the VEGFR-3 ligand causes primary congenital lymphedema (91), leading to prolonged pressure to formation lymphatic obstruction. The production and activation of VEGF and its receptor suggest their involvement in lymphatic thrombosis (92). An as yet unknown cascade of lymphatic thrombosis evoked by the lymphatic specific factor VEGFR-3 either alone or in conjunction with other control elements awaits further exploration.

**Table 1** | Hemostatic properties in human plasma and lymph.

|                          | Plasma | Lymph | References |
|--------------------------|--------|-------|------------|
| Platelets                | Yes    | No    | (42)       |
| von Willebrand factor    | High   | Low   | (62)       |
| Coagulation factors activity | High   | Low   | (43)       |
| D-dimers activity        | Low    | High  | (53)       |
| Antithrombins activity   | Low    | High  | (79)       |
| TFPIs activity           | Low    | High  | (43)       |
LYMPHATIC THROMBOSIS-RELATED DISEASES

Lymphedema
Lymphedema is a chronic and persistent disease that can easily lead to a large number of comorbidities (93). It may be caused by mechanical obstruction or destruction of the lymphatic wall that leads to abnormal accumulation and overloading of interstitial fluid containing high-molecular-weight proteins (94). Lymphedema is the long-term stasis of fluid in the lymphatic vessels, causing lymph nodes to continue to contract due to the increase in volume. In lymphedema, lymphatic valve function and smooth muscle contraction gradually deteriorate, leading to the weakening of unilateral lymph fluid propulsion, forming a vicious circle; the continuous swelling in the lymphatic vessels and the blocking of proteins lead to fibrosis, which might trigger the formation of fibrinoid and occlusive thrombosis in the lumen (46, 95). In severe cases, cellulitis may occur (96). However, lymphatic injury and dissection are not the only causes of lymphedema (97). Some studies have shown that mutations in coagulation factor V combined with other susceptible factors may cause lymphatic thrombosis and lead to lymphedema (98). The causal association between thrombus and lymphedema is unclear. One possibility is that lymphatic thrombosis develops first and induces lymphedema. Another possibility is that lymphatic stasis and lymphedema develop first, and thrombus forms due to reduced low flow in the occluded lymphatic vessels (50). Nevertheless, it is certain that the edema is caused, at least in part, by interruption of lymph flow (42, 49).

Amyloidosis
In cases studies of amyloidosis, a total of 2% of patients diagnosed with all types of amyloidosis had lymph node amyloidosis (99, 100). Both von Willebrand factor and factor V were identifiable in areas of lymph node amyloid deposition by immunohistochemistry. This research providing evidence that the adsorption of coagulation factors from the circulation into the lymphatic vessels by extracellular deposition of pathologic amyloid. This pathological changes result in an acquired factor deficiency and thus the cause of the bleeding disorder (101). The adsorption of coagulation factors from the circulation into the lymph by amyloid lymphadenopathy may lead to the formation of lymphatic thrombosis. These studies may help explain the unclear pathogenesis of lymphadenopathy and related lymphatic thrombosis.

Infection
In an experiment on liver and gallbladder edema caused by cantharidin, liver lymphatic vessels expanded extensively. Lymphatic endothelial cells are damaged and denatured under the action of poison, which forms a fibrous network in lymphatic vessels to block lymph flow (82). Other fungal, bacterial and viral infectionsmay cause cellulitis or progressive lymphatic destruction, which sporadically predispose to thrombosis of lymph vessels. The common infections are lymphatic filariasis or sustained by chlamydia trachomatis, mycobacterium tuberculosis, treponemapallidium, or streptococcus pyogenes (46). Among them, the inflammatory response and lymphatic endothelial damage triggered by the nematode infection is a major factor in the pathogenesis of lymphatic thrombosis in lymphatic filariasis (102, 103).

Cancer
Different mechanisms may lead to lymphatic thrombosis or occlusion in cancer patients, including external compression from tumor masses, neoplastic occlusion of lymphatic vessels by metastatic cells or lymphatic dysfunction afterlymphadenectomy (46). Coagulation after lymph node dissection continues to be a frequently reported morbidity (104). The tissue injury from surgery releases tissue factor that may cause hypercoagulability in the surrounding lymph. The outflow obstruction induced by removal of axillary lymphatics draining the arm would be generated stasis of lymphovenous channels. The pathology demonstrated fibrin clot in lymphatics of biopsied axillary webs (105). Therefore, lymphatic thrombosis maybe a significant cause of axillary web syndrome in the early postoperative period for patients after axillary lymph node dissection.

Sporadiccases
Patients with chronic venous insufficiency, deep vein thrombosis, venous valve damage may develop persistent inflammation and chronic damage to the lymphatic vessel, leading to loss of lymphatic vessel contraction function, reduced lymphatic drainage, and severe lymphatic thrombosis (106). The condition is often complicated by concurrent cellulitis and inflammation of the distal lower limb (95). When the function of the lymphovenous valve is impaired, platelet-mediated thrombosis occurs, preventing further lymphatic venous reflux, producing lymphatic stasis, and causing lymphatic obstruction (107). However, this may lead to thoracic outlet syndrome or complications that require central venous catheterization or coronary artery bypass grafting (108, 109). Congenital or acquired thoracic duct outflow obstruction (secondary to central venous thrombosis or injury during cardiothoracic surgery) is the cause of high morbidity and mortality in newborns (110).

DISCUSSION
Although lymphatic thrombosis occurs in a variety of diseases, it has rarely been reported. For cancer lymphatic thrombosis, the leading causes include external tumor compression, neoplastic obliteration by metastatic cells, or lymphatic injury after lymph node dissection. Patients with fungal, bacterial and viral infections in tissues near lymphatic vessels may have lymphatic thrombosis and progressive lymphatic destruction. Lymphatic thrombosis was also found in sporadic cases of complications of central venous thrombosis or injury during cardiothoracic surgery, chronic venous insufficiency and thoracic outlet syndrome, which accompanied with lymphatic venous valve injury or obstruction of thoracic catheter drainage. If the lymphatics thrombosis causes accumulation of interstitial fluid, the lymphatico-venous anastomosis is expected to reduce the inner pressure of the lymphatic vessel and reconstruct lymph flow. For patients with severe, unexplained edema, clinicians may consider the possibility of the lymphatic thrombosis. Indocyanine green lymphography and radionuclide
lymphoscintigraphy may locate lymphatic obstruction, while laboratory tests are still limited. Many cases of lymphatics thrombosis were found in lymphatic biopsy. Further studies are needed to understand the mechanisms of lymphatic thrombosis and develop novel diagnostic and therapeutic strategies.

**AUTHOR CONTRIBUTIONS**

JLiu conceived and designed the review. JLiu, WZ, and JT wrote the first draft. JLi, JLia, and XQ participated in writing of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Nature Science Foundation of China (81873473 and 91939110), Academic Promotion Program of Shandong First Medical University (2019QL014) and Shandong Taishan Scholarship (JLiu).

**REFERENCES**

1. Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K. Lymphatic system in cardiovascular medicine. Circ Res. (2016) 118:315–30. doi: 10.1161/CIRCRESAHA.115.306544
2. Hsu MC, Itkin M. Lymphatic anatomy. Tech Vasc Interv Radiol. (2016) 19:247–54. doi: 10.1053/j.tjv.2016.10.003
3. Hu D, Li L, Li S, Wu M, Ge N, Cui Y, et al. Lymphatic system identification, pathophysiology and therapy in the cardiovascular diseases. J Mol Cell Cardiol. (2019) 133:99–111. doi: 10.1016/j.yjmcc.2019.06.002
4. Skobe M, Deimar M. Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc. (2000) 5:14–9. doi: 10.1046/j.1097-0223.2000.00001.x
5. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost. (2008) 34:747–61. doi: 10.1055/s-0029-1145257
6. Blomstrand R, Nilsson IM, Dahlback O. Coagulation studies on human thoracic duct lymph. Scand J Clin Lab Invest. (1963) 15:248–54. doi: 10.3109/03007967090797470
7. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol. (1896) 19:312–26. doi: 10.1113/jphysiol.1896.sp000596
8. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis and development: bridging the gaps. Carcinogenesis. (2006) 27:1729–38. doi: 10.1093/carcin/bgl031
9. Schauden J, Harvey NL. Morphogenesis of the lymphatic vasculature: a focus on new progenitors and cellular mechanisms important for constructing lymphatic vessels. Dev Dyn. (2016) 245:209–19. doi: 10.1002/dvdy.24313
10. Trzeciak J, Mallippatu SK, Artmann GM, Delano FA, Schmid-Schonbein GW. Evidence for a second valve system in lymphatics: endothelial microvalves. FASEB J. (2001) 15:1711–7. doi: 10.1096/fasebj.01-0067com
11. Zawieja DC. Contractile physiology of lymphatics. Lymphat Res Biol. (2009) 7:87–96. doi: 10.1089/lrb.2009.0007
12. Trevaskis NL, Kaminiskas LM, Porter CJ. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nut Rev Drug Discov. (2015) 14:781–803. doi: 10.1038/nrd4608
13. Hargens AR, Zweifach BW. Contractile stimuli in collecting lymph vessels. Am J Physiol. (1977) 233:H57–65. doi: 10.1152/ajpheart.1977.233.1.H57
14. Oliszewski WL, Engeset SA. Intrinsic contractility of prenodal lymph vessels and lymph flow in human leg. Am J Physiol. (1980) 239:H775–83. doi: 10.1152/ajpheart.1980.239.6.H775
15. Sharda AV, Barr AM, Harrison JA, Wilkie AR, Fang C, Mendez LM, et al. VWF maturation and release are controlled by two regulators of weibel-palade body biogenesis: exocyst and BLOC-2. Blood. (2020) 136:2824–37. doi: 10.1182/blood.2020053000
37. Wagner DD. Cell biology of von willebrand factor. *Annu Rev Cell Biol.* (1990) 6:217–46. doi: 10.1146/annurev.cb.06.110190.001245

38. Andrews RK, Berndt MC. Platelet physiology and thrombosis. *Thromb Res.* (2004) 114:447–53. doi: 10.1016/j.thromres.2004.07.020

39. Lancellotti S, Sacco M, Basso M, De Cristofaro R. Mechanochemistry of von willebrand factor. *Biomol Concepts.* (2019) 10:194–208. doi: 10.1515/bmc-2019-0022

40. Rodgers GM. Hemostatic properties of normal and perturbed vascular cells. *FASEB J.* (1988) 2:116–23. doi: 10.1096/fasebj.2.2.3277885

41. Gross PL, Aird WC. The endothelium and thrombosis. *Semin Thromb Hemost.* (2000) 26:463–78. doi: 10.1055/s-2000-13202

42. Opie EL. Thrombosis and occlusion of lymphatics. *J Med Res.* (1913) 29:131–46.

43. Le DT, Borga P, Tonell TW, Witte MH, Rapaport SI. Hemostatic relationships with occlusion and thrombosis. *Semin Thromb Hemost.* (2012) 38:213–21. doi: 10.1055/s-0032-1301418

44. Lippi G, Favaloro EJ. Coagulopathies and thrombosis: usual and unusual causes and associations, part VI. *Semin Thromb Hemost.* (2012) 38:8–9. doi: 10.1055/s-0032-1301409

45. Yamakawa M, Takagi M, Tajima K, Ohe S, Osanai T, Kudo S, et al. Localization of blood coagulation factors and fibrinolysis factors within lymphoid germinal centers in human lymph nodes. *Hisiochemistry.* (1991) 96:123–7. doi: 10.1007/BF00319982

46. Lippi G, Favaloro EJ, Cervellin G. Hemostatic properties of the lymph: relationships with occlusion and thrombosis. *Semin Thromb Hemost.* (2012) 38:213–21. doi: 10.1055/s-0032-1301418

47. Hara H, Mihara M, Seki Y, Koshima I. Lymphoedema caused by idiopathic lymphoendothelial characteristics in murine embryos. *Dev Dyn.* (2006) 235:1554–62. doi: 10.1002/dvdy.20737

48. Mahadevan A, Welsh IC, Sivakumar A, Gludish DW, Shilvock AR, Noden DM, et al. The left-right Pitx2 pathway drives organ-specific arterial and lymphatic development in the intestine. *Dev Cell.* (2014) 31:690–706. doi: 10.1016/j.devcel.2014.11.002

49. Ahn SM, Simpson RJ. Body fluid proteomics: prospects for biomarker discovery. *Proteomics Clin Appl.* (2007) 1:1004–15. doi: 10.1002/prca.200700217

50. Hara H, Mihara M, Ohtomo R, Tanaka S. Lymphatic vessel thrombosis in a 60-year-old bullmastiff bitch with vaginal prolapse, primary lymph node distichiasis. *J Clin Invest.* (2000) 106:1144–52. doi: 10.1172/JCI70422

51. Johansson K, Chong H, Ciornei CD, Brorson H, Mortimer PS. Axillary web syndrome: evidence for lymphatic origin with thrombosis. *Lymphat Res Biol* (2007) 2:107–17. doi: 10.1016/S2005-2901(09)60042-X

52. Miller NE, et al. An expanded self-antigen peptide peptidome is carried by human lymph as compared to the plasma. *PLoS ONE.* (2010) 5:e9863. doi: 10.1371/journal.pone.0009863

53. Marchetti C, Poggio P, Calligaro A, Casasco A. Lymphatic vessels of the human dental pulp in different conditions. *Anat Rec.* (1992) 234:27–33. doi: 10.1002/ar.1092930104

54. Qi Q, Wang Z, Wang D, Wang W. [Ultrastructure of the lymph capillaries in human dental pulp]. *Hua Xi Kou Qiang Yi Xue Za Zhi.* (2000) 18:222–5. doi: 10.3321/j.isn.1000-1182.2000.04.004

55. Gerli R, Secciani I, Sozio F, Rossi A, Weber E, Lorenzini G. Absence of lymphatic vessels in human dental pulp: a morphological study. *Eur J Oral Sci.* (2010) 10:118–22. doi: 10.1111/j.1600-0722.2010.00592.x

56. Williams JH, Birrell I, Wilms J. Lymphangiogenesis in a 3.5-year-old bullmastiff bitch with vaginal prolapse, primary lymph node fibrosis and other congenital defects. *J S Afr Vet Assoc.* (2005) 76:165–71. doi: 10.4102/jsava.v76i3.420

57. Ogay V, Rae KH, Kim KW, Soh KS. Comparison of the characteristic features of bonghan ducts, blood and lymphatic capillaries. *J Acupunct Meridian Stud.* (2009) 2:107–17. doi: 10.1007/s12025-909(09)60042-X

58. Koina ME, Baxter L, Adamson SJ, Arfuso F, Hu P, Madigan MC, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. *Nat Med.* (2004) 10:974–81. doi: 10.1038/nm1094

59. Hess PR, Rawlsney DR, Jakus Z, Yang Y, Sweet DT, Fu J, et al. Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. *J Clin Invest.* (2014) 124:273–84. doi: 10.1172/JCI70422

60. Kopec AK, Luyendyk JP. Coagulation in liver toxicity and disease: role of hepatocyte tissue factor. *Thromb Res.* (2014) 1(Suppl. 133):S57–9. doi: 10.1016/j.thromres.2014.03.023

61. Wilting J, Aref Y, Huang R, Tomarev SI, Schweigerer L, Christ B, et al. Dual origin of avian lymphatics. *Dev Biol.* (2006) 292:162–73. doi: 10.1016/j.ydbio.2005.12.043

62. Bernier-Latmani J, Sabine A, Petrova TV. Meet me in the middle: dual origins and lymphatic development in the intestine. *Dev Cell.* (2014) 31:690–706. doi: 10.1016/j.devcel.2014.11.002

63. Muller N, Danckworth HP. [Coagulation properties of the extravascular fluid. I. Coagulation factors in thoracic-duct lymph]. *Z Lymphol.* (1967) 234:27–43.

64. Null M, Agarwal M. *Anatomy, Lymphatic System In StatPearls.* Treasure Island (FL): StatPearls Publishing (2021).

65. Ohtani O, Ohtani Y. Lymph circulation in the liver. *Anat Rec.* (2008) 291:643–52. doi: 10.1002/ar.20691

66. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. *Semin Liver Dis.* (2002) 22:83–96. doi: 10.1055/s-2002-23205

67. Groth CG, Hathaway WE, Gustafsson A, Geis WP, Putnam CW, Bjorken C, et al. Correction of coagulation in the hemophilic dog by transplantation of lymphoid germinal centers in human lymph nodes. *Histochemistry.* (2013) 100:201–11. doi: 10.1515/bmc-2019-0022

68. Chromes RH, Liew FY, Diprose WA. Biodegradable copolymers for drug delivery in lymphatic disease. *Surgery.* (1974) 75:275–33.

69. Everitt LA, Cleuren AC, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. *Blood.* (2014) 123:3697–705. doi: 10.1182/blood-2014-02-55401
82. Bach-Ganso ET, Godal HC, Skonsberg OH. Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex Dimer test. *Thromb Res.* (1998) 92:125–34. doi: 10.1016/S0049-3848(98)00121-2

83. Wittner AN, Dai J, Weich HA, Vrensen GF, Schlingemann RO. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. *J Histochem Cytochem.* (2002) 50:767–77. doi: 10.1177/002215540205000603

84. Fedele C, Berens D, Raunefeldt V, Pabst R. Desmoplin and plakoglobin–specific markers of lymphatic vessels in the skin? *Anat Histochem Embryol.* (2004) 33:168–71. doi: 10.1111/j.1439-0264.2004.00529.x

85. Becker J, Tchagou Tchangou GE, Schmidt S, Zelent C, Kahl E, Wilting J. Absence of lymphatic vessels in term placenta. *BMC Pregnancy Childbirth.* (2020) 20:380. doi: 10.1186/s12884-020-03073-w

86. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? *Microsc Res Tech.* (2001) 55:61–9. doi: 10.1002/jemt.1157

87. Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. *Hematol Am Soc Hematol Educ Program.* (2019) 2019:175–81. doi: 10.1182/hematology.2019001388

88. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, et al. Evidence of both von willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis. *Blood Coagul Fibrinol.* (2017) 28:342–7. doi: 10.1097/MRC.0000000000000600

89. Fader RC, Ewert A. Evolution of lymph thrombi in experimental brugia malayi infections: a scanning electron microscopic study. *Lymphology.* (1986) 19:146–52.

90. Case T, Leis B, Witte M, Way D, Bernas M, Borgs P, et al. Vascular abnormalities in experimental and human lymphatic filariasis. *Lymphology.* (1999) 24:174–83.

91. Shaitelman SF, Cromwell KD, Rasmussen JC, Stout NL, Armer JM, Lasisi BB, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. *CA Cancer J Clin.* (2015) 65:55–81. doi: 10.3322/caac.21253

92. Moskovitz AH, Anderson BO, Yeung RS, Byrd DR, Lawton TJ, Roe RE. Axillary web syndrome after axillary dissection. *Ann Surg.* (2001) 181:434–9. doi: 10.1096/jso.2001.100602-X

93. Boutu EM, Bell RD, Rahimi H, Xing L, Wood RW, Bingham et al. Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis. *Nat Rev Rheumatol.* (2018) 14:94–106. doi: 10.1038/nrrheum.2017.205

94. Kunze G, Staritz M. Lymph vessel thrombus detection in cervical lymphedema: a case series. *J Ultrasound Med.* (2017) 36:1955–1960. doi: 10.1002/jum.14249

95. Hinckley ME. Thoracic-duct thrombosis with fatal chylothorax caused by a long venous catheter. *N Engl J Med.* (1969) 280:95–6. doi: 10.1056/NEJM196901092800210

96. Maldonado F, Hawkins FJ, Daniels CE, Doerr CH, Decker PA, Ryu JH. Pleural fluid characteristics of chylothorax. *Mayo Clin Proc.* (2009) 84:129–33. doi: 10.4065/84.2.129

97. Reisen R, Kovach SJ, Levin LS, Pinto E, Nadolski GJ, Itkin M, et al. Thoracic duct-to-vein anastomosis for the management of thoracic duct outflow obstruction in newborns and infants: a CASE series. *J Pediatr Surg.* (2020) 55:234–9. doi: 10.1016/j.jpedsurg.2019.10.029

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Li, Li, Tian and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.